Toggle Main Menu Toggle Search

Open Access padlockePrints

Defective B cell ontogeny and immune response in human complement receptor 2 (CR2, CD21) transgenic mice is partially recovered in the absence of C3

Lookup NU author(s): Professor Kevin MarchbankORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Mice prematurely expressing human CR2 (hCR2) in the B cell lineage have a defective B cell ontogeny and immune response. Our recent analysis of this phenotype suggested that signaling through hCR2 and presumably mouse CD19 on the B cell surface, during bone marrow development, could result in the observed changes in B cell function in these mice. To test this hypothesis, we back crossed hCR2high transgenic mice onto the CD19-/- background. CD19-/-hCR2high mice were found to possess even fewer mature B cells than their CD19+/+hCR2high littermates, demonstrating that loss of CD19 exacerbated the effects elicited through hCR2. This data suggests that CD19 provides a survival signal during B cell development in this model. Next, we examined if the removal of the main ligand for CR2, namely C3d, through back-crossing onto the C3-/- background could restore normal B cell development. However, we found only minor recovery in peripheral B cell numbers and no obvious change in function. This was despite a three-fold increase in the level of hCR2 expression on B cells isolated from the spleen or bone marrow of C3-/-hCR2high mice when compared with C3 sufficient littermates. These data demonstrate that hCR2 is integrated in mouse B cell signaling and that the downstream effects of hCR2 expression during early B cell development are partially but not completely due to interaction with C3 fragments and signaling through CD19 in the bone marrow environment. © 2007 Elsevier Ltd. All rights reserved.


Publication metadata

Author(s): Twohig J, Kulik L, Haluszczak C, Reuter J, Rossbach A, Bull M, Holers VM, Marchbank KJ

Publication type: Article

Publication status: Published

Journal: Molecular Immunology

Year: 2007

Volume: 44

Issue: 13

Pages: 3434-3444

ISSN (print): 0161-5890

ISSN (electronic): 1872-9142

Publisher: Pergamon

URL: http://dx.doi.org/10.1016/j.molimm.2007.02.011

DOI: 10.1016/j.molimm.2007.02.011

PubMed id: 17379312


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Wellcome Trust
068541Wellcome Trust
R01 CA053615-08NCI NIH HHS
R01 CA53615NCI NIH HHS
T32 GM008497-14NIGMS NIH HHS
R01 CA053615NCI NIH HHS
T32 GM008497NIGMS NIH HHS

Share